Funder: Food and Drug Administration (FDA)

Due Dates: August 8, 2025 (Full Application)

Funding Amounts: Up to $500,000 per year for up to 3 years; total program funding up to $1.5M; 1–3 awards expected

Summary: Supports applied regulatory science research to improve detection and monitoring of cardiotoxicity from oncology therapeutics.

Key Information: Foreign organizations and non-U.S. components are not eligible; clinical trial optional.